Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. - Abstract - Europe PMC
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Tankyrase inhibitors as antitumor agents: a patent update (2013 – 2020)
令癌莎- Wikiwand
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian ca
763113-22-0 Olaparib - Watson International Ltd
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
COH34 is a potent and cell-active PARG inhibitor. (A) Predicted... | Download Scientific Diagram
Olaparib | AZD-2281 | CAS#763113-22-0 | MedKoo
令癌莎- Wikiwand
HemOnc.org | A Hematology Oncology Wiki
A Wikipedia edit-a-thon for women in cancer research
Olaparib - Wikipedia
BRCA Support Liverpool
Olaparib CAS 763113-22-0 Watson International Limited
PARP inhibitor - Wikipedia
HemOnc.org | A Hematology Oncology Wiki
Olaparib: Cos'è, A Cosa Serve, Quando si Assume
Supplementary appendix
Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis | Crystal Growth & Design
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment - ScienceDirect
